GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

VRCA · Jun 30, 2025

Verrica Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0000950170-25-107358General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

193.50% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-79.07% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

145.35% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

19.86% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating margin88thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.operating_margin

11.89% · CORE · VALID

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

14.53% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensity13thOwn-history percentile · N=8

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

6.99% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Sep 30, 20230/8 normalizedLevel 3 Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/8 normalizedLevel 3 Jun 30, 20240/9 normalizedLevel 3 Sep 30, 20240/5 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20252/7 normalizedLevel 3 Dec 31, 20257/8 normalizedLevel 3 Mar 31, 20265/6 normalizedLevel 3 Jun 30, 20265/6 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 808.64%
Current: 193.50%
Delta: -615.14%

Cash Generation Increased

Previous: -368.62%
Current: -79.07%
Delta: 289.55%

Growth Increased

Previous: -10.12%
Current: 145.35%
Delta: 155.47%

Inventory Pressure Decreased

Previous: 71.50%
Current: 19.86%
Delta: -51.65%

Profitability Increased

Previous: -236.41%
Current: 11.89%
Delta: 248.29%

R And D Intensity Decreased

Previous: 66.41%
Current: 14.53%
Delta: -51.88%

Sbc Intensity Decreased

Previous: 29.83%
Current: 6.99%
Delta: -22.84%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Has State · Verrica Pharmaceuticals Inc. →Transitioned To · VRCA Fundamental State →Transitioned To · VRCA BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · VRCA CASH_GENERATION_INCREASED →Transitioned To · VRCA GROWTH_INCREASED →Transitioned To · VRCA INVENTORY_PRESSURE_DECREASED →Transitioned To · VRCA PROFITABILITY_INCREASED →Transitioned To · VRCA R_AND_D_INTENSITY_DECREASED →Transitioned To · VRCA SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.